November 14 @ 6:00 pm – 7:30 pm
40 Rector Street, 2nd Floor, New York, NY 10006

Gary Rieschel, Founder of Qiming Venture Partners, Olivia Wang, Head of U.S. for ZhenFund, and Fei Wang, Cornell Medical health data mining and machine learning expert, discuss how big data and other health innovations have investors rushing for China

Wednesday, November 14, 6:00–7:30 PM
Speakers: Gary Rieschel, Olivia Wang, Fei Wang
Moderator: Ye Xie

From Ant Financial’s insurance claims and CT image reading apps to China’s largest online health care platform Ping An Good Doctor’s IPO in Hongkong, China is experiencing a health care boom, and health care startups are sizzling. China’s endless Big Data pool, coupled with hungry entrepreneurialism, are driving all sorts of health care innovation. Who will be the next unicorn startup? What are the opportunities and challenges in the field? Will China’s top-down technology policies make the country a fierce competitor for global technology supremacy?

Join Gary Rieschel, Founder of Qiming Venture Partners, and Olivia Wang, Head of U.S. for ZhenFund, to learn how China technology and Big Data are disrupting health care.

Moderator Bio
Ye Xie Ye Xie is a journalist from Bloomberg News, with 18 years of reporting experience in the U.S. and China. Ye has been writing about global financial markets since joining Bloomberg in 2006, covering subjects from global currencies, Brazilian bonds to Chinese stocks. He currently writes for the Markets Live blog, which provides real-time market analysis for Bloomberg’s 325,000 terminal users. Prior to Bloomberg, he worked at China Daily in Beijing as an energy-industry reporter.

Ye holds a MS in journalism from Ohio University and a BA in international business communications from Nanjing University in China. He is a chartered financial analyst.

Speakers Bios
Gary Rieschel has more than 25 years of investing experience as a senior executive, entrepreneur, investor, and global business strategist. During his career, Rieschel has held executive positions at Intel, Sequent Computer, Cisco Systems, and Softbank Corporation. Over the last 20 years as a venture capitalist, he led investments in 12 companies that grew to over $1B USD in market capitalization. Rieschel aided in the creation of the venture capital industry in China through sponsoring and founding several of China’s leading VC firms, including Softbank China Ventures, SAIF Partners (2001), Ceyuan Ventures (2004), and Qiming Venture Partners (2006). He is Founding Managing Partner of Qiming, a firm with more than $3B USD focused on early stage investments in China. Rieschel’ s personal investment areas are Healthcare and Cleantech. He has sponsored investments in imaging systems (Alltech), clinical trial execution, fuel cells (Bloom Energy), industrial waste water treatment (CSD Water and Sludge), clean coal technologies (LP Amina), smart meters (Hexin), and bioengineering (Lanzatech). Qiming launched a U.S.-based health care fund in 2017.

Rieschel holds a BA in Biology from Reed College in Portland, OR, and an MBA from the Harvard Business School. He lived in Japan for five years in the late 1980s and lived in Shanghai from 2005 through 2016. He now lives in Seattle, WA.

Olivia Wang is an investor and Head of US for ZhenFund, a leading early stage venture fund in China. She has led investments in startups including UBiome, Xtalpi, Synthego, and Transcriptic. In 2016, after spending two years on the deal team in Beijing, Olivia moved to Silicon Valley to start ZhenFund’s US office and oversee its cross-border investments. Previously, Olivia worked at Huobi, a Sequoia China-backed bitcoin exchange that is top ten in global liquidity, and she currently serves on the company’s board of directors. She started her career on the Asia Equity Sales Desk at Credit Suisse. As an alumna of John Hopkins University, Olivia is an active member of the Hopkins crossborder biotech community. She was named one of Forbes’ “30 Under 30” for venture capital in 2017.

Fei Wang is an Assistant Professor in Cornell University’s Division of Health Informatics, Department of Healthcare Policy and Research, Weill Cornell Medicine. His major research interest is data mining, machine learning methodologies, as well as their applications in health data science. He won the Parkinson’s Progression Markers’ Initiative data challenge organized by the Michael J. Fox Foundation, and NIPS 2017 challenge on Classification of Clinically Actionable Genetic Mutations. Dr. Wang is the chair-elect of the KDD working group in AMIA. Dr. Wang is an action editor of the journal Data Mining and Knowledge Discovery, an associate editor of Journal of Health Informatics Research, Smart Health, Pattern Recognition and IEEE Transactions on Neural Networks and Learning Systems. Dr. Wang has applied for more than 40 US patents, among which 15 are granted.